Full-Time

Associate Director

Global Real-World Evidence, Oncology

Deadline 9/20/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

+ Long-term incentive program

Raritan, NJ, USA

Hybrid

Hybrid work is required in Raritan, New Jersey; approximately 10% travel is required, primarily domestic with some international travel.

Master's, PhD

Category
Biology & Biotech
Required Skills
Python
SAS
Data Visualization
Data Science
R
Electronic Health Records (EHR)
Biostatistics
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • An advanced degree in epidemiology, pharmacoepidemiology, health economics and outcomes research, public health, biostatistics, health policy, health services research, or a related field is required.
  • A minimum of 5 years of relevant experience in the pharmaceutical, biotechnology, consulting, academic, or healthcare environment is required, with experience in real-world evidence, epidemiology, outcomes research, medical affairs, market access, or related functions.
  • Demonstrated experience supporting the design and execution of real-world evidence studies, including observational studies, retrospective database analyses, evidence synthesis, protocol development, analytic planning, interpretation of results, and scientific dissemination.
  • Strong working knowledge of real-world data sources and fit-for-purpose real-world evidence methods is required, including claims databases, electronic health records, registries, chart reviews, and other healthcare data sources.
  • Ability to provide methodological input on observational study design, analytic approaches, bias mitigation, data interpretation, and communication of real-world evidence findings to technical and non-technical audiences is required.
  • Experience collaborating with programmers, statisticians, epidemiologists, real-world evidence researchers, cross-functional partners, and external vendors to execute data-driven research projects is required.
  • Strong project management skills are required, including the ability to manage timelines, coordinate deliverables, track decisions and actions, support governance processes, and drive execution in a matrixed global environment.
  • Strong communication, presentation, and scientific writing skills are required, with the ability to translate complex research concepts and data-driven insights into clear messages for internal and external stakeholders.
  • Experience contributing to publications, congress presentations, internal evidence-generation deliverables, or other scientific communication outputs is required.
Responsibilities
  • Support the Global Real-World Evidence Disease Lead in developing and maintaining Integrated Evidence Generation Plans and long-range Worldwide Real-World Evidence Roadmaps for assigned disease areas and assets.
  • Drive high-quality execution of priority real-world evidence studies and evidence-generation projects, ensuring timely delivery, scientific rigor, operational excellence, and appropriate interpretation and dissemination of study outputs.
  • Collaborate with real-world evidence researchers, programmers, cross-functional partners, regional and local evidence-generation teams, and external vendors to translate study concepts into protocols, analyses, deliverables, publications, and other evidence-dissemination materials.
  • Support the Disease Lead in global and regional stakeholder management across cross-functional workstreams, real-world evidence working groups, Evidence Labs, and project execution forums.
  • Serve as a methodology subject matter expert in assigned cross-functional workstreams, providing scientific input on real-world data sources, observational study designs, analytic approaches, fit-for-purpose evidence methods, and best practices.
  • Analyze, interpret, and synthesize real-world data, literature, competitive evidence, and stakeholder insights to inform evidence-gap assessments, strategic trade-off discussions, urgent business requests, and cross-functional decision-making.
  • Contribute to real-world evidence operational governance, standards, processes, and operating models by supporting prioritization, resource planning, deliverable tracking, review processes, vendor oversight, and consistency across disease- and asset-level activities.
  • Ensure assigned real-world evidence activities comply with applicable regulatory, legal, privacy, publication, and commercial requirements while upholding scientific integrity, responsible communication, and evidence dissemination.
Desired Qualifications
  • A PhD is preferred.
  • Experience with global, multi-country real-world evidence studies is preferred.
  • Hands-on experience with SAS, R, Python, or other statistical programming tools is preferred.
  • Oncology experience is strongly preferred.
  • Working knowledge of the global healthcare, reimbursement, payer, medical affairs, and evidence-generation environment is preferred, particularly as it relates to oncology product strategy and stakeholder evidence needs.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.